Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Google DeepMind's spinoff Isomorphic Labs is set to begin human trials of a drug desinged completely by Artificial ...

Isomorphic Labs advances towards human clinical trials for AI-designed drugs, marking a pivotal moment in pharmaceutical ...